Evan Seigerman
Stock Analyst at BMO Capital
(3.68)
# 936
Out of 4,413 analysts
83
Total ratings
50%
Success rate
6.25%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $129 → $138 | $141.47 | -2.45% | 8 | May 2, 2024 | |
| INCY Incyte | Maintains: Market Perform | $56 → $52 | $52.65 | -1.23% | 6 | May 1, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $55 → $48 | $43.85 | +9.46% | 7 | Apr 26, 2024 | |
| IRON Disc Medicine | Maintains: Outperform | n/a | $28.62 | - | 4 | Apr 2, 2024 | |
| BIIB Biogen | Maintains: Outperform | $295 → $285 | $215.02 | +32.55% | 11 | Feb 14, 2024 | |
| LLY Eli Lilly | Maintains: Outperform | $710 → $865 | $768.86 | +12.50% | 5 | Feb 7, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $389 → $415 | $400.51 | +3.62% | 10 | Nov 7, 2023 | |
| GILD Gilead Sciences | Upgrades: Outperform | $90 → $100 | $65.52 | +52.63% | 8 | May 16, 2023 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $39.10 | +2.30% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $6.51 | +514.91% | 1 | Oct 14, 2022 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $757 → $788 | $917.32 | -14.10% | 9 | Aug 4, 2022 | |
| NUVB Nuvation Bio | Downgrades: Market Perform | $8 → $2.5 | $3.22 | -22.24% | 2 | Aug 2, 2022 | |
| AMGN Amgen | Maintains: Market Perform | $263 → $243 | $277.55 | -12.45% | 5 | Apr 28, 2022 | |
| CADL Candel Therapeutics | Maintains: Outperform | $18 → $12 | $7.75 | +54.94% | 1 | Mar 31, 2022 | |
| PFE Pfizer | Initiates: Outperform | n/a | $27.70 | - | 1 | Nov 19, 2021 | |
| IKNA Ikena Oncology | Initiates: Outperform | n/a | $1.31 | - | 1 | Apr 20, 2021 | |
| GRTX Galera Therapeutics | Upgrades: Outperform | n/a | $0.19 | - | 2 | Dec 16, 2020 | |
| MGNX MacroGenics | Maintains: Outperform | n/a | $15.28 | - | 1 | May 6, 2020 |
Neurocrine Biosciences
May 2, 2024
Maintains: Market Perform
Price Target: $129 → $138
Current: $141.47
Upside: -2.45%
Incyte
May 1, 2024
Maintains: Market Perform
Price Target: $56 → $52
Current: $52.65
Upside: -1.23%
Bristol-Myers Squibb Company
Apr 26, 2024
Maintains: Market Perform
Price Target: $55 → $48
Current: $43.85
Upside: +9.46%
Disc Medicine
Apr 2, 2024
Maintains: Outperform
Price Target: n/a
Current: $28.62
Upside: -
Biogen
Feb 14, 2024
Maintains: Outperform
Price Target: $295 → $285
Current: $215.02
Upside: +32.55%
Eli Lilly
Feb 7, 2024
Maintains: Outperform
Price Target: $710 → $865
Current: $768.86
Upside: +12.50%
Vertex Pharmaceuticals
Nov 7, 2023
Maintains: Outperform
Price Target: $389 → $415
Current: $400.51
Upside: +3.62%
Gilead Sciences
May 16, 2023
Upgrades: Outperform
Price Target: $90 → $100
Current: $65.52
Upside: +52.63%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $39.10
Upside: +2.30%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $6.51
Upside: +514.91%
Regeneron Pharmaceuticals
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $917.32
Upside: -14.10%
Nuvation Bio
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $3.22
Upside: -22.24%
Amgen
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $277.55
Upside: -12.45%
Candel Therapeutics
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $7.75
Upside: +54.94%
Pfizer
Nov 19, 2021
Initiates: Outperform
Price Target: n/a
Current: $27.70
Upside: -
Ikena Oncology
Apr 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.31
Upside: -
Galera Therapeutics
Dec 16, 2020
Upgrades: Outperform
Price Target: n/a
Current: $0.19
Upside: -
MacroGenics
May 6, 2020
Maintains: Outperform
Price Target: n/a
Current: $15.28
Upside: -